Literature DB >> 16523001

Class effects and labeling of antihypertensive drugs.

Thomas G Pickering1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16523001      PMCID： PMC8109415          DOI： 10.1111/j.1524-6175.2005.05122.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  38 in total

1.  Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

Authors:  P Svensson; U de Faire; P Sleight; S Yusuf; J Ostergren
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

Review 2.  What lessons can be learnt from withdrawal of mibefradil from the market?

Authors:  A L Po; W Y Zhang
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

3.  A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.

Authors:  Y Lacourcière; R Asmar
Journal:  Am J Hypertens       Date:  1999-12       Impact factor: 2.689

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Authors:  B M Brenner; M E Cooper; D de Zeeuw; J P Grunfeld; W F Keane; K Kurokawa; J B McGill; W E Mitch; H H Parving; G Remuzzi; A B Ribeiro; M D Schluchter; D Snavely; Z Zhang; R Simpson; D Ramjit; S Shahinfar
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2000-12       Impact factor: 1.636

6.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

Authors:  C D Furberg; B M Psaty; J V Meyer
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

7.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.

Authors:  Philip A Poole-Wilson; Jacobus Lubsen; Bridget-Anne Kirwan; Fred J van Dalen; Gilbert Wagener; Nicolas Danchin; Hanjörg Just; Keith A A Fox; Stuart J Pocock; Tim C Clayton; Michael Motro; John D Parker; Martial G Bourassa; Anthony M Dart; Per Hildebrandt; Ake Hjalmarson; Johannes A Kragten; G Peter Molhoek; Jan-Erik Otterstad; Ricardo Seabra-Gomes; Jordi Soler-Soler; Simon Weber
Journal:  Lancet       Date:  2004 Sep 4-10       Impact factor: 79.321

8.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Authors:  Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Jacobus Lubsen; Beatrix Lutiger; Marco Metra; Willem J Remme; Christian Torp-Pedersen; Armin Scherhag; Allan Skene
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

9.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

10.  New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-03       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.